iTeos Therapeutics’ (ITOS) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note released on Wednesday,RTT News reports. Wedbush currently has a $25.00 price target on the stock.

A number of other equities analysts also recently commented on ITOS. Wells Fargo & Company decreased their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, January 16th.

iTeos Therapeutics Stock Up 6.0 %

Shares of NASDAQ:ITOS opened at $7.26 on Wednesday. The business has a fifty day simple moving average of $7.54 and a 200-day simple moving average of $9.55. iTeos Therapeutics has a 52 week low of $6.67 and a 52 week high of $18.75. The company has a market cap of $265.24 million, a P/E ratio of -2.30 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. Sell-side analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ITOS. Point72 DIFC Ltd acquired a new stake in shares of iTeos Therapeutics in the third quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $42,000. Virtus ETF Advisers LLC increased its holdings in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares in the last quarter. Forefront Analytics LLC bought a new position in iTeos Therapeutics in the 4th quarter valued at $85,000. Finally, Graham Capital Management L.P. bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at about $85,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.